$1.84
2.79% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Inventiva - ADR Stock price

$1.84
-0.59 24.28% 1M
-1.98 51.83% 6M
-2.68 59.26% YTD
-2.32 55.77% 1Y
-12.35 87.03% 3Y
-11.58 86.29% 5Y
-11.58 86.29% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.05 2.79%
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Key metrics

Market capitalization $93.74m
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 5.55
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 17.91%
Revenue (TTM) Revenue $16.89m
EBIT (operating result TTM) EBIT $-110.07m
EPS (TTM) EPS $-2.23
P/E forward negative
P/S forward 15.49
Short interest 0.46%
Show more

Is Inventiva - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Inventiva - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Inventiva - ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Inventiva - ADR forecast:

Buy
86%
Hold
14%

Financial data from Inventiva - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
17 17
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
28% 28%
93%
- Research and Development Expense 110 110
26% 26%
650%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -110 -110
22% 22%
-652%
Net Profit -113 -113
33% 33%
-667%

In millions USD.

Don't miss a Thing! We will send you all news about Inventiva - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inventiva - ADR Stock News

Neutral
GlobeNewsWire
2 days ago
Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases w...
Neutral
GlobeNewsWire
about 2 months ago
Daix (France), Long Island City (New York, United States), July 31, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with s...
Neutral
GlobeNewsWire
2 months ago
Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH...
More Inventiva - ADR News

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Head office France
CEO Frédéric Cren
Employees 123
Founded 2011
Website www.inventivapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today